{"id":68003,"date":"2026-06-11T20:36:10","date_gmt":"2026-06-11T12:36:10","guid":{"rendered":"https:\/\/flcube.com\/?p=68003"},"modified":"2026-06-11T20:36:12","modified_gmt":"2026-06-11T12:36:12","slug":"imviva-biotech-receives-fda-clearance-for-phase-1b-basket-trial-of-cta313-allogeneic-car-t-therapy-in-b-cell-mediated-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68003","title":{"rendered":"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Imviva Biotech<\/strong> announced it has received <strong>Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)<\/strong> to initiate a <strong>Phase 1b basket clinical trial<\/strong> evaluating <strong>CTA313<\/strong>, an <strong>allogeneic &#8220;off-the-shelf&#8221; chimeric antigen receptor (CAR)-T cell therapy<\/strong>, for the treatment of multiple <strong>B cell-mediated autoimmune diseases<\/strong>, including <strong>systemic lupus erythematosus (SLE)<\/strong>, <strong>progressive multiple sclerosis (pMS)<\/strong>, and <strong>autoimmune encephalitis (AE)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-development-milestone\" class=\"wp-block-heading\">Regulatory &amp; Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Imviva Biotech (China-based, private)<\/td><\/tr><tr><td><strong>Therapy<\/strong><\/td><td>CTA313 (allogeneic CAR-T cell therapy)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance for clinical investigation<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Phase 1b basket study<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), autoimmune encephalitis (AE)<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Safety, efficacy, and cellular pharmacokinetics<\/td><\/tr><tr><td><strong>Parallel Development<\/strong><\/td><td>Investigator-initiated trials (IITs) ongoing in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-platform-amp-innovation\" class=\"wp-block-heading\">Technology Platform &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Technology:<\/strong> Proprietary ANSWER suppressive ligand platform combined with advanced gene-editing technologies<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Enhanced resistance to host immune rejection, improving treatment durability and persistence<\/li>\n\n\n\n<li><strong>Manufacturing Model:<\/strong> True &#8220;off-the-shelf&#8221; allogeneic approach \u2013 single batch can treat multiple patients<\/li>\n\n\n\n<li><strong>Logistical Advantage:<\/strong> Pre-manufactured and cryopreserved for immediate availability, eliminating patient-specific manufacturing delays<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> B cells driving autoimmune pathology across multiple disease states<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">CTA313 represents a paradigm shift in CAR-T therapy development, moving beyond oncology applications into the challenging autoimmune disease space. By leveraging Imviva&#8217;s ANSWER platform to overcome traditional allogeneic CAR-T limitations\u2014including host immune rejection and limited persistence\u2014the therapy offers potential for durable disease modification rather than symptomatic management.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Disease Market:<\/strong> Combined addressable population exceeds 2 million patients in the U.S. alone across the three initial indications<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> First allogeneic CAR-T therapy to enter clinical development for SLE and pMS; addresses significant unmet needs in treatment-refractory populations<\/li>\n\n\n\n<li><strong>Commercial Advantage:<\/strong> Off-the-shelf model enables scalable manufacturing and immediate treatment access, contrasting with autologous CAR-T&#8217;s 3-6 week manufacturing timeline<\/li>\n\n\n\n<li><strong>Pricing Potential:<\/strong> Expected premium pricing reflecting curative potential and manufacturing efficiency; estimated $200,000-$300,000 per treatment course<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Positions Imviva at the forefront of next-generation cell therapy expansion beyond oncology into chronic autoimmune conditions<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> FDA clearance accelerates international regulatory strategy, with European Medicines Agency (EMA) submission anticipated by Q1 2027<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The basket trial design allows efficient evaluation across multiple autoimmune indications simultaneously, potentially accelerating development timelines and maximizing resource utilization for this innovative therapeutic approach.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities. Actual outcomes may differ due to clinical trial results, regulatory decisions, and competitive developments inherent in novel cell therapy development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,4788],"class_list":["post-68003","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-imviva-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b basket clinical trial evaluating CTA313, an allogeneic &quot;off-the-shelf&quot; chimeric antigen receptor (CAR)-T cell therapy, for the treatment of multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68003\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b basket clinical trial evaluating CTA313, an allogeneic &quot;off-the-shelf&quot; chimeric antigen receptor (CAR)-T cell therapy, for the treatment of multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68003\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T12:36:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T12:36:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68003#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68003\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases\",\"datePublished\":\"2026-06-11T12:36:10+00:00\",\"dateModified\":\"2026-06-11T12:36:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68003\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Imviva Biotech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68003#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68003\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68003\",\"name\":\"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-11T12:36:10+00:00\",\"dateModified\":\"2026-06-11T12:36:12+00:00\",\"description\":\"Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b basket clinical trial evaluating CTA313, an allogeneic \\\"off-the-shelf\\\" chimeric antigen receptor (CAR)-T cell therapy, for the treatment of multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68003#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68003\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68003#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b basket clinical trial evaluating CTA313, an allogeneic \"off-the-shelf\" chimeric antigen receptor (CAR)-T cell therapy, for the treatment of multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68003","og_locale":"en_US","og_type":"article","og_title":"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases","og_description":"Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b basket clinical trial evaluating CTA313, an allogeneic \"off-the-shelf\" chimeric antigen receptor (CAR)-T cell therapy, for the treatment of multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE).","og_url":"https:\/\/flcube.com\/?p=68003","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-11T12:36:10+00:00","article_modified_time":"2026-06-11T12:36:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68003#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68003"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases","datePublished":"2026-06-11T12:36:10+00:00","dateModified":"2026-06-11T12:36:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68003"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Imviva Biotech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68003#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68003","url":"https:\/\/flcube.com\/?p=68003","name":"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-11T12:36:10+00:00","dateModified":"2026-06-11T12:36:12+00:00","description":"Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b basket clinical trial evaluating CTA313, an allogeneic \"off-the-shelf\" chimeric antigen receptor (CAR)-T cell therapy, for the treatment of multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68003#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68003"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68003#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68003"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68003\/revisions"}],"predecessor-version":[{"id":68004,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68003\/revisions\/68004"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}